|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2011-3-31
|
|
pubmed:abstractText |
Infliximab is effective maintenance for moderate to severe Crohn's disease (CD); however, problems with immunogenicity and decreased efficacy often complicate long-term use. Durability of infliximab maintenance therapy over multiple years has not been defined.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1536-4844
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2009 Crohn's & Colitis Foundation of America, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1837-43
|
|
pubmed:meshHeading |
pubmed-meshheading:19462426-Adult,
pubmed-meshheading:19462426-Antibodies, Monoclonal,
pubmed-meshheading:19462426-Crohn Disease,
pubmed-meshheading:19462426-Female,
pubmed-meshheading:19462426-Gastrointestinal Agents,
pubmed-meshheading:19462426-Humans,
pubmed-meshheading:19462426-Male,
pubmed-meshheading:19462426-Middle Aged,
pubmed-meshheading:19462426-Retrospective Studies,
pubmed-meshheading:19462426-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Durability of infliximab in Crohn's disease: a single-center experience.
|
|
pubmed:affiliation |
Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
